BCL2 and prostate carcinoma: Others have shown that in vitro treatment with I3C or DIM inhibits NFκB activity in human breast and prostate cancer cells undergoing apoptosis [18], [50] and reduces BCL-2 mRNA and protein expression in breast cancer cells [51].